Fig. 7: ULBP2 CAR-T cells alone or in combination with anti-PD-1 improves survival of NSG mice bearing patient-derived xenografts. | Cell Death & Disease

Fig. 7: ULBP2 CAR-T cells alone or in combination with anti-PD-1 improves survival of NSG mice bearing patient-derived xenografts.

From: ULBP2 CAR-T cells enhance gastric cancer immunotherapy by inhibiting CAF activation

Fig. 7: ULBP2 CAR-T cells alone or in combination with anti-PD-1 improves survival of NSG mice bearing patient-derived xenografts.The alternative text for this image may have been generated using AI.

A Diagram of the experimental procedure. B–D Tumor growth B and survival curves (C, D) of mice bearing the PDX from a patient treated with ULBP2 CAR-T or ctrl cells alone, or ULBP2 CAR-T cells plus anti-PD-1 (n = 5). E Representative images of H&E, Ki-67 IHC, CD8 IHC, Masson, and α-SMA IF staining in the PDX mice that received different treatments. F–I Quantification of Ki-67 F (n = 3), CD8+T cells G (n = 6), collagen area H (n = 6), and α-SMA area (n = 3) in the PDX at day 21 post tumor inoculation. Data are represented as mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001).

Back to article page